Entera Bio Outlines Pivotal Osteoporosis Trial, Names New CEO

0
25

  • Following its End of Phase 2 Meeting with the FDA, Entera Bio Ltd (NASDAQ: ENTX) has designed the pivotal study for EB613 as an 18-month double-blind placebo-controlled study, followed by a 6-month open-label transition to alendronate for all patients.
  • The study's primary endpoint employs the Foundation for the National Institutes of Health Bone Quality Program (FNIH BQP) total hip Bone Mineral Density (BMD) as a surrogate endpoint …

Full story available on Benzinga.com

LEAVE A REPLY

Please enter your comment!
Please enter your name here